Scientists and researchers belonging to the Indian Medical Council (ICMR) announced that they are working on the first contraceptive vaccine for men and that they planning to launch it in the next seven months. This release date is far ahead of research in the United States and the United Kingdom because the ICMR seems to have completed all relevant clinical trials.
The new intramuscular contraceptive, called reversible inhibitor and sperm under guidance (Risug), is based on a sperm inhibitor, based on a maleic styrene anhydride. The injection is applied near the testicles, with anesthesia in between the groin where it can reach the vas deferens, a pair of muscular tubes that connect the epididymis with the ejaculatory ducts, blocking the passage of semen.
“Non-surgical procedures are always preferred because they are safer and also less invasive, which is why we believe that more men will opt for these soon,” said Dr. Anup Kumar, Head of the Department of Urology and Renal Transplantation at Safdarjung Medical Center.
The ICMR reported that the injection was applied to 303 patients, in which a total success rate of 97.3% was achieved.
Now, after two years of scientific tests with more than 300 candidates, Dr. RS Sharma, responsible for the project, says that this treatment is now ready to go on the market.
The injection is effective between 10 and 13 years and the side effects are: acne, increased sexual desire and mild mood swings.
